Canada markets closed

Charles River Laboratories International, Inc. (CRL)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
227.55-2.54 (-1.10%)
At close: 04:00PM EDT
227.55 0.00 (0.00%)
After hours: 04:30PM EDT

Charles River Laboratories International, Inc.

251 Ballardvale Street
Wilmington, MA 01887
United States
781 222 6000

IndustryDiagnostics & Research
Full Time Employees20,400

Key Executives

NameTitlePayExercisedYear Born
Ms. Flavia H. PeaseCorporate Executive VP & CFO1.66MN/A1973
Ms. Birgit GirshickCorporate Executive VP & COO1.28M464.88k1970
Mr. Joseph W. LaPlumeCorporate Executive Vice President of Corporate Development & Strategy928.36k262.98k1974
Mr. William D. BarboCorporate Executive Vice President of Community Relations1M399.92k1961
Mr. Michael Gunnar KnellCorporate Senior VP & Chief Accounting OfficerN/AN/A1977
Prof. Julie Frearson Ph.D.Corporate Senior VP & Chief Scientific OfficerN/AN/AN/A
Mr. Mark MintzCorporate Senior VP & Chief Information OfficerN/AN/AN/A
Todd SpencerCorporate Vice President of Investor RelationsN/AN/AN/A
Mr. Matthew L. DanielCorporate Senior VP, General Counsel, Corporate Secretary & Chief Compliance OfficerN/AN/AN/A
Ms. Amy CianciarusoCorporate Vice President & Chief Communications OfficerN/AN/AN/A
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Corporate Governance

Charles River Laboratories International, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.